Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Invariant Natural Killer T Cells by Beijing Gene Key Life Technology for Hepatocellular Carcinoma: Likelihood of Approval
Invariant Natural Killer T Cells is under clinical development by Beijing Gene Key Life Technology and currently in Phase II...